Our People

Ron Levy, MD Clinical Advisor

Dr. Levy is Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. His research focuses on the interplay between the immune system and lymphomas. He was the first to use the unique idiotype as a target of the immune system.

Dr. Levy's research led to the development of rituximab, a B-cell lymphoma treatment. He continues to study the mechanism of lymphoma initiation and progression to develop new therapies. In recent years he has conducted significant research into the use of Toll-Like Receptor agonists to stimulate immune responses to target lymphoma.

Dr. Levy's honors include the Damashek Prize, American Society of Hematology; Jeffrey A. Gottlieb Award, MDAnderson Cancer Center; Evelyn Hoffman Award, Lymphoma Research Foundation; Medal of Honor, American Cancer Society; and membership in the National Academy of Science and the National Academy of Medicine.

Dr. Levy received an AB from Harvard University and an MD from Stanford University, completed residency at Massachusetts General Hospital and a fellowship at Stanford, and is Board certified in oncology and internal medicine.

Back to All